tissueguard.de

What It Is

TissueGUARD GmbH is a German company spun out of the Leibniz Institute of Polymer Research Dresden in 2019. Based on the captured website text, it positions itself as an FDA-registered medical device company focused on ophthalmic corneal-transplant injectors and accessories, as well as hydrogels and cell-culture consumables for tissue engineering, cell therapy, and organoid research. It is worth noting that the site content does not match the “cybersecurity” category: there are no descriptions of capabilities such as firewalls, endpoint security, identity security, vulnerability management, cloud security, or security operations.

Core Capabilities and Compliance

From a medical device perspective, TissueGUARD’s core product is the DMEK Injector Set. It is compatible with both Endo-out and Endo-in DMEK techniques, supplied as a sterile kit, and recommended for 2.4-2.6 mm corneal incisions. Related products include the Tip Closure Cap, DMEK/DSAEK Washing GUARD, and training/education kits. On the regulatory side, the DMEK Injector is an FDA-listed medical device in the United States and is commercially available; several accessories are also FDA-listed accessories in the U.S. In the EU, most CE medical device certifications are still expected in 2026 or 2027, and some products are currently available only as lab equipment or for research use.

Pricing and Target Users

The website discloses pricing for a number of individual products: the DMEK Injector Set is $184 in the U.S. and €160 + VAT in the EU; the closure caps are $50 per box of 10 in the U.S. and €45 in the EU; the Washing GUARD is $50 per box of 5 in the U.S. and €45 in the EU; and the training kit is $99 in the U.S. and €80 in the EU. Harvesting Plate and TGel also have clear pricing. The intended users are mainly corneal surgeons, eye-bank technicians, ophthalmic medical institutions, and tissue-engineering or organoid research laboratories—not enterprise IT or security teams.

Pros and Cons

The main advantage is that the product pages clearly disclose intended use, regulatory status, specifications, and pricing, while offering a combination of devices and accessories around DMEK/DSAEK use cases. The drawbacks are that EU CE certification has not yet been completed, and some products are not yet on the market or are not approved for human use. From a cybersecurity review perspective, there is no information about protection type, deployment model, management and alerting, or integration capabilities, so it cannot be assessed as a security product for procurement.

China Access and Alternatives

The text does not provide information on access from China, payment methods, distributors, or localized support, so direct availability and procurement channels in China are unknown. Users looking for cybersecurity products should instead consider vendors in firewalls, EDR, SASE, WAF, vulnerability management, or SIEM/SOAR. Users looking for ophthalmic medical devices should further verify China registration certificates, import channels, clinical scope of use, and after-sales support.